Aug 18, 2025, 07:40

Cholangiocarcinoma Foundation — Career Development Award

Three-year award to help mid-career investigators establish independent cholangiocarcinoma research programs. Total funding USD 300,000 (USD 100,000/year).

Eligibility Criteria:

Doctoral degree (MD, PhD, MD/PhD or equivalent) and full-time independent appointment at an academic/clinical/research institution (any country).
In ≥4th year of primary faculty appointment; not yet in a major leadership role (e.g., chair/division chief/center director).
Clinicians: active medical license in the country of research.
Evidence of early independent productivity (e.g., leading projects/clinical trials, PI/co-PI funding, lead-author publications).
ICRN member or membership application submitted with the grant.
Commit ≥75% full-time effort to research during the award period.
Institutional mentor required (include support letter; if mentor is not ICRN, add a letter from an ICRN member).
In good standing with any prior CCF grants; only one active CCF grant at a time.
Not eligible with concurrent federal career development or institutional training awards (e.g., K08/K23, T32, KL2/K12). Prior early-career CDAs may still be eligible if time/independence criteria are met and not yet at senior-investigator status.
No concurrent private-foundation career development awards during the CDA term; time-in-rank prorated for documented interruptions.

Funding Details:

USD 300,000 total over 3 years (annual USD 100,000 installments).
May support personnel, research expenses, and travel to the CCF Annual Conference.
Award term: Jan 1, 2026 – Dec 31, 2028.

Deadline:

LOI opens: Aug 1, 2025.
Application deadline: Aug 22, 2025.

Where to Go for Further Information:

See the Cholangiocarcinoma Foundation Career Development Award call for full instructions, eligibility clarifications, and submission steps.

bile duct cancer cancer Career Development Award CCF cholangiocarcinoma Cholangiocarcinoma Foundation ICRN mid-career investigators OncoDaily Oncology research funding

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth